Whitney & Co’s Jazz Pharmaceuticals JAZZ Stock Holding History

Whitney & Co’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-100	Closed	-$14K	–	277
2018 Q3	$14K	Buy	+100	New	+$17.2K	﹤0.01%	288

Other funds holding JAZZ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TCIM

TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Whitney & Co's JAZZ Position: Q4 2018 in Review

Whitney & Co sold out of Jazz Pharmaceuticals (JAZZ) in Q4 2018, closing a stake of 100 shares — an estimated $14K sold.

Whitney & Co first reported a position in JAZZ in Q3 2018 and held it in 1 quarter. The position peaked at $14K in Q3 2018. 417 funds tracked by Wall St. Rank hold JAZZ as of Q4 2018.

Whitney & Co reported no remaining Jazz Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Whitney & Co sold 100 Jazz Pharmaceuticals shares in Q4 2018, an estimated $14K.
Whitney & Co first reported a position in Jazz Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Whitney & Co's Jazz Pharmaceuticals position peaked at $14K in Q3 2018.
417 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q4 2018.

Based on Whitney & Co's 13F filing for Q4 2018, filed 7 Feb 2019.